lapatinib has been researched along with l 733060 in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (l 733060) | Trials (l 733060) | Recent Studies (post-2010) (l 733060) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 71 | 0 | 32 |
| Protein | Taxonomy | lapatinib (IC50) | l 733060 (IC50) |
|---|---|---|---|
| Substance-P receptor | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
1 other study(ies) available for lapatinib and l 733060
| Article | Year |
|---|---|
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |